

CV Sciences Certificate of Analysis



This document is to certify that units of the lot number below were tested and found to comply with CV Sciences finished product specifications.

PRODUCT NAME:	SAMPLE ID:
Strength:	Expiration Date:
Lot Number:	Total Quantity Produced:

PHYSICAL PROPERTIES	STATUS (PASS/FAIL)	METHOD
Appearance		
Color		
Aroma		

CANNABINOIDS*	MG/UNIT	METHOD
CBD		
CBDA		
d9-THC		
THCA-A		
d8-THC		
THCV		
CBDV		
CBDVA		
CBGA		
CBG		
CBN		
CBC		
CBL		
Total Cannabinoids		
Unit Weight		
THC by Mass		

OTHER ACTIVE INGREDIENTS**	MG/UNIT	METHOD
Palmitoylethanolamide (PEA)		

HEAVY METALS*	STATUS (PASS/FAIL)	METHOD
Arsenic		
Cadmium		
Mercury		
Lead		

CV Sciences Certificate of Analysis



MICROBIOLOGY*	STATUS (PASS/FAIL)	METHOD
Mold/Mildew/Yeast		
Aerobic Bacteria		
Coliforms		
E. Coli		
Salmonella		
Pseudomonas		

PESTICIDES***	STATUS (PASS/FAIL)	METHOD
Total Pesticides		

RESIDUAL SOLVENTS***	STATUS (PASS/FAIL)	METHOD
Total Residual Solvents		

1. The hemp extract is the product of a batch tested by the independent testing laboratory;
2. The batch contained a total delta-9-tetrahydrocannabinol concentration that did not exceed 0.3 percent pursuant to the testing of random sample of the batch; and
3. The batch does not contain contaminants unsafe for human consumption.[†]

[†]Tested analytes and limits were set by CV Sciences, Inc.

DB Labs Sample ID #:

*Actual analytical results obtained by DB Labs (Las Vegas, NV), CV Sciences' third-party testing laboratory.

Advanced Botanical Consulting & Testing Sample ID #:


**Actual analytical results obtained by Advanced Botanical Consulting & Testing, Inc. (Tustin, CA), CV Sciences' third-party testing laboratory.


Anresco Laboratories Sample ID #:

***Actual analytical results obtained by Anresco Laboratories (San Francisco, CA), CV Sciences' third-party testing laboratory.

*This Certificate of Analysis has been generated to document product test results.
The "Prepared By" signature does not indicate finished product release for distribution.*

QUALITY APPROVAL

Prepared By / Date	Approved By / Date	Status
Vandana Kothari	 DocuSigned by Vandana Kothari I approve this document 22-Jul-2024 10:44 PDT 87A410FF03248738900BEED0868E359	



July 15, 2024

CV SCIENCES, INC.9530 Padgett Street, Suite 107
San Diego, CA 92126Order No. 558528
Sample No. 1230459

SAMPLE INFORMATION

Description FP-24-0061 Relief Softgels 60ct SKU 608 exp 02/26
Lot Number : A106950624
Category (Type) Non-Inhalable Edible (Capsule)
Received July 11, 2024

ANALYTICAL RESULTS

Analysis Pesticide Screen ✔ Pass
Instrument Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)
Method MF-CHEM-13
Analysis Date July 11, 2024 to July 15, 2024

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
Abamectin	0.04/0.10	ND	0.3	Pass
Acephate	0.02/0.06	ND	5.0	Pass
Acequinocyl	0.04/0.10	ND	4.0	Pass
Acetamiprid	0.017/0.05	ND	5.0	Pass
Aldicarb	0.02/0.06	ND	0.02	Pass
Azoxystrobin	0.02/0.06	ND	40.0	Pass
Bifenazate	0.02/0.06	ND	5.0	Pass
Bifenthrin	0.04/0.10	ND	0.5	Pass
Boscalid	0.02/0.06	ND	10.0	Pass
Captan	0.2/0.6	ND	5.0	Pass
Carbaryl	0.02/0.06	ND	0.5	Pass
Carbofuran	0.017/0.05	ND	0.017	Pass
Chlorantraniliprole	0.02/0.06	ND	40.0	Pass
Chlordane	0.02/0.06	ND	0.02	Pass
Chlorfenapyr	0.02/0.06	ND	0.02	Pass
Chlorpyrifos	0.02/0.06	ND	0.02	Pass
Clofentezine	0.02/0.06	ND	0.5	Pass
Coumaphos	0.02/0.06	ND	0.02	Pass
Cyfluthrin	0.10/0.30	ND	1.0	Pass
Cypermethrin	0.10/0.30	ND	1.0	Pass
Daminozide	0.017/0.05	ND	0.017	Pass
DDVP (Dichlorvos)	0.013/0.04	ND	0.013	Pass
Diazinon	0.017/0.05	ND	0.2	Pass
Dimethoate	0.017/0.05	ND	0.017	Pass
Dimethomorph	0.017/0.05	ND	20.0	Pass
Ethoprop(hos)	0.02/0.06	ND	0.02	Pass
Etofenprox	0.02/0.06	ND	0.02	Pass
Etoxazole	0.02/0.06	ND	1.5	Pass
Fenhexamid	0.017/0.05	ND	10.0	Pass
Fenoxycarb	0.02/0.06	ND	0.02	Pass
Fenpyroximate	0.02/0.06	ND	2.0	Pass

If there are any questions with this report, please contact "compliance@anresco.com".

Certificate of Analysis

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
Fipronil	0.02/0.06	ND	0.02	Pass
Flonicamid	0.02/0.06	ND	2.0	Pass
Fludioxonil	0.02/0.06	ND	30.0	Pass
Hexythiazox	0.02/0.06	ND	2.0	Pass
Imazalil	0.02/0.06	ND	0.02	Pass
Imidacloprid	0.02/0.06	ND	3.0	Pass
Kresoxim Methyl	0.02/0.06	ND	1.0	Pass
Malathion	0.017/0.05	ND	5.0	Pass
Metalaxyl	0.017/0.05	ND	15.0	Pass
Methiocarb	0.02/0.06	ND	0.02	Pass
Methomyl	0.013/0.04	ND	0.1	Pass
Methyl parathion	0.02/0.06	ND	0.02	Pass
Mevinphos	0.02/0.06	ND	0.02	Pass
Myclobutanil	0.02/0.06	ND	9.0	Pass
Naled	0.017/0.05	ND	0.5	Pass
Oxamyl	0.013/0.04	ND	0.2	Pass
Paclobutrazol	0.02/0.06	ND	0.02	Pass
Pentachloronitrobenzene	0.017/0.05	ND	0.2	Pass
Permethrins	0.10/0.30	ND	20.0	Pass
Phosmet	0.02/0.06	ND	0.2	Pass
Piperonyl Butoxide	0.017/0.05	ND	8.0	Pass
Prallethrin	0.04/0.10	ND	0.4	Pass
Propiconazole	0.02/0.06	ND	20.0	Pass
Propoxur	0.013/0.04	ND	0.013	Pass
Pyrethrins	0.15/0.50	ND	1.0	Pass
Pyridaben	0.017/0.05	ND	3.0	Pass
Spinetoram	0.02/0.06	ND	3.0	Pass
Spinosad	0.02/0.06	ND	3.0	Pass
Spiromesifen	0.04/0.10	ND	12.0	Pass
Spirotetramat	0.02/0.06	ND	13.0	Pass
Spiroxamine	0.017/0.05	ND	0.017	Pass
Tebuconazole	0.02/0.06	ND	2.0	Pass
Thiacloprid	0.013/0.04	ND	0.013	Pass
Thiamethoxam	0.02/0.06	ND	4.5	Pass
Trifloxystrobin	0.02/0.06	ND	30.0	Pass

Reported by
Anresco, Inc.

ND = None Detected
 LOD = Limit of Detection
 LOQ = Limit of Quantitation


 Alda Tan
 Analyst III



July 15, 2024

If there are any questions with this report, please contact "compliance@anresco.com".

July 15, 2024

CV SCIENCES, INC.9530 Padgett Street, Suite 107
San Diego, CA 92126Order No. 558528
Sample No. 1230459

SAMPLE INFORMATION

Description FP-24-0061 Relief Softgels 60ct SKU 608 exp 02/26
Lot Number : A106950624
Category (Type) Non-Inhalable Edible (Capsule)
Received July 11, 2024

ANALYTICAL RESULTS

Analysis Residual Solvent Screen ✔ Pass
Instrument Gas Chromatography Mass Spectrometry (GC/MS)
Method MF-CHEM-32
Analysis Date July 11, 2024 to July 15, 2024

Analyte	LOD/LOQ (ppm)	Findings (ppm)	Limit (ppm)	Status
1,2-Dichloroethane	0.5/0.5	ND	1	Pass
Acetone	57/200	ND	5000	Pass
Acetonitrile	56/200	ND	410	Pass
Benzene	0.5/0.5	ND	1	Pass
n-Butane	45/200	ND	5000	Pass
Chloroform	0.5/0.5	ND	1	Pass
Ethanol	37/200	ND	5000	Pass
Ethyl acetate	38/200	ND	5000	Pass
Ethyl ether	37/200	ND	5000	Pass
Ethylene oxide	0.1/0.5	ND	1	Pass
n-Heptane	135/200	ND	5000	Pass
n-Hexane	49/200	ND	290	Pass
Isopropyl alcohol	57/200	ND	5000	Pass
Methanol	37/200	ND	3000	Pass
Methylene chloride	0.1/0.5	ND	1	Pass
n-Pentane	37/200	ND	5000	Pass
Propane	72/200	ND	5000	Pass
Toluene	49/200	ND	890	Pass
Total xylenes (ortho-, meta-, para-)	58/200	ND	2170	Pass
Trichloroethylene	0.5/0.5	ND	1	Pass

Reported by
Anresco, Inc.

ND = None Detected
LOD = Limit of Detection
LOQ = Limit of Quantitation



Jordean Vargas
Analyst III

July 15, 2024

If there are any questions with this report, please contact "compliance@anresco.com".


July 15, 2024

CV SCIENCES, INC.9530 Padgett Street, Suite 107
San Diego, CA 92126Order No. 558528
Sample No. 1230459

SAMPLE INFORMATION

Description FP-24-0061 Relief Softgels 60ct SKU 608 exp 02/26
Lot Number : A106950624
Category (Type) Non-Inhalable Edible (Capsule)
Received July 11, 2024

ANALYTICAL RESULTS

Analysis Cannabinoid Profile (Non-Plant)  **Pass**
Instrument Liquid Chromatography Diode Array Detector (LC-DAD)
Method MF-CHEM-15
Analysis Date July 11, 2024 to July 15, 2024

Cannabinoid	mg/g	%	mg/serving	mg/package	Status
Δ8-THC	ND	ND	ND	ND	-
Δ9-THC	<LOQ	<LOQ	<LOQ	<LOQ	Pass
Δ9-THCA	ND	ND	ND	ND	-
THCV	ND	ND	ND	ND	-
THCVA	ND	ND	ND	ND	-
CBD	40.51	4.051	23.28	1396.88	-
CBDA	23.84	2.384	13.70	821.95	-
CBC	<LOQ	<LOQ	<LOQ	<LOQ	-
CBCA	ND	ND	ND	ND	-
CBDV	<LOQ	<LOQ	<LOQ	<LOQ	-
CBG	ND	ND	ND	ND	-
CBGA	<LOQ	<LOQ	<LOQ	<LOQ	-
CBN	ND	ND	ND	ND	-
Total THC	<LOQ	<LOQ	<LOQ	<LOQ	-
Total CBD	61.42	6.142	35.30	2117.72	-
Total Cannabinoids	61.42	6.142	35.30	2117.72	-
Sum of Cannabinoids	64.35	6.435	36.98	2218.82	-
Serving Weight (g)	0.5747				
Package Weight (g)	34.48				

Comments

Sample is tested with only filling, the average weight of the softgel is 0.8562 g and the average filling weight is 0.5747 g.
This result of this sample is confirmed with a retest.

Reported by
Anresco, Inc.
Ali Sweeney
Analyst II

ND = None Detected
LOD = Limit of Detection (0.1333 mg/g)
LOQ = Limit of Quantitation (0.4000 mg/g)
Total THC = Δ8-THC + Δ9-THC + (0.877 * THCA)
Total CBD = CBD + (0.877 * CBDA)
Total Cannabinoids = Σ (neutral cannabinoids) + [0.877 * Σ (acidic cannabinoids)]

July 15, 2024

If there are any questions with this report, please contact "compliance@anresco.com".



Certificate of Analysis

July 15, 2024

CV SCIENCES, INC.
9530 Padgett Street, Suite 107
San Diego, CA 92126

Order No. 558528
Sample No. 1230459

SAMPLE INFORMATION

Description FP-24-0061 Relief Softgels 60ct SKU 608 exp 02/26
Lot Number : A106950624
Category (Type) Non-Inhalable Edible (Capsule)
Received July 11, 2024

ANALYTICAL RESULTS

Analysis Mycotoxins Screen ✔ Pass
Instrument Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) & Gas Chromatography Tandem Mass Spectrometry (GC-MS/MS)
Method MF-CHEM-13
Analysis Date July 11, 2024 to July 15, 2024

Analyte	LOD/LOQ (ppb)	Findings (ppb)	Limit (ppb)	Status
Aflatoxin B1	2/5	ND	-	-
Aflatoxin B2	2/5	ND	-	-
Aflatoxin G1	2/5	ND	-	-
Aflatoxin G2	2/5	ND	-	-
Total Aflatoxins	8/20	ND	20	Pass
Ochratoxin A	6/18	ND	20	Pass

Reported by
Anresco, Inc.

ND = None Detected
LOD = Limit of Detection
LOQ = Limit of Quantitation


Alda Tan
Analyst III



July 15, 2024

If there are any questions with this report, please contact "compliance@anresco.com".

July 15, 2024

CV SCIENCES, INC.

9530 Padgett Street, Suite 107
San Diego, CA 92126

Order No. 558528
Sample No. 1230459

SAMPLE INFORMATION

Description FP-24-0061 Relief Softgels 60ct SKU 608 exp 02/26
Lot Number : A106950624
Received July 11, 2024

ANALYTICAL RESULTS

Analysis Date July 11, 2024 to July 15, 2024

Findings	Analysis	Results	Method
	Standard Plate Count	<10 cfu/g	FDA BAM
	Yeast	<10 cfu/g	FDA BAM
	Mold	<10 cfu/g	FDA BAM
	Coliforms	<10 cfu/g	FDA BAM - ECC AGAR
	Escherichia coli	<10 cfu/g	FDA BAM - ECC AGAR
	Salmonella	Negative /25g	MF-MICRO-11 (AOAC 2016.01)
	Staph aureus	Negative /10g	USP <62>

Reported by
Anresco, Inc.



Allen Zhu
Analyst

If there are any questions with this report, please contact "compliance@anresco.com".

page 1 of 1

July 15, 2024

CV SCIENCES, INC.

9530 Padgett Street, Suite 107
San Diego, CA 92126

Order No. 558528
Sample No. 1230460

SAMPLE INFORMATION

Description FP-24-0062 PlusCBD 50mg 60ct Softgels SKU 391 exp 07/25
Lot Number A106960624
Received July 11, 2024

ANALYTICAL RESULTS

Analysis Date July 11, 2024 to July 15, 2024

Findings	Analysis	Results	Method
	Standard Plate Count	<10 cfu/g	FDA BAM
	Yeast	<10 cfu/g	FDA BAM
	Mold	<10 cfu/g	FDA BAM
	Coliforms	<10 cfu/g	FDA BAM - ECC AGAR
	Escherichia coli	<10 cfu/g	FDA BAM - ECC AGAR
	Salmonella	Negative /25g	MF-MICRO-11 (AOAC 2016.01)
	Staph aureus	Negative /10g	USP <62>

Reported by
Anresco, Inc.



Allen Zhu
Analyst

If there are any questions with this report, please contact "compliance@anresco.com".

page 1 of 1



Certificate of Analysis

March 26, 2024

CV SCIENCES, INC.
9530 Padgett Street, Suite 107
San Diego, CA 92126

Order No. 553948
Sample No. 1200506

SAMPLE INFORMATION

Description IP-24-0004 30mg Relief softgel inprocess bulk exp 02/26
Lot Number C2400128
Category (Type) Non-Inhalable Edible (Capsule)
Received March 13, 2024

ANALYTICAL RESULTS

Analysis PEA
Instrument LC-MS/MS
Method Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain, Journal of Neuroinflammation 2014, 11:136
Analysis Date March 13, 2024 to March 26, 2024

Analyte	Findings (mg/softgel)
Palmitoylethanolamide	195

Reported by
Anresco, Inc.

ND = None Detected
LOD = Limit of Detection
LOQ = Limit of Quantitation




Cathy Cheng
Senior Analyst

March 26, 2024

If there are any questions with this report, please contact "compliance@anresco.com".

Certificate Of Completion		
Envelope Id: D03C15C883414B129C8BC6AA37F30AD6	Status: Completed	
Subject: FP-24-0061 Relief Softgels 60ct SKU 608 exp 02/26 A106950624		
Source Envelope:		
Document Pages: 10	Signatures: 1	Envelope Originator:
Certificate Pages: 1	Initials: 0	Vandana Kothari
AutoNav: Enabled		vandana.kothari@cvsciences.com
Envelopeld Stamping: Enabled		IP Address: 64.207.219.136
Time Zone: (UTC-08:00) Pacific Time (US & Canada)		

Record Tracking		
Status: Original	Holder: Vandana Kothari	Location: DocuSign
7/22/2024 10:39:16 AM	vandana.kothari@cvsciences.com	

Signer Events	Signature	Timestamp
Vandana Kothari vandana.kothari@cvsciences.com DIRECTOR OF QUALITY CV Sciences - Part 11 Security Level: Email, Account Authentication (Required)	 Signature Adoption: Pre-selected Style Signature ID: 87A410FF-F032-4873-8900-BEED0868E359 Using IP Address: 75.85.176.253 With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document	Sent: 7/22/2024 10:39:54 AM Viewed: 7/22/2024 10:42:26 AM Signed: 7/22/2024 10:45:03 AM

Electronic Record and Signature Disclosure:
Not Offered via DocuSign

In Person Signer Events	Signature	Timestamp
Editor Delivery Events	Status	Timestamp
Agent Delivery Events	Status	Timestamp
Intermediary Delivery Events	Status	Timestamp
Certified Delivery Events	Status	Timestamp
Carbon Copy Events	Status	Timestamp
Witness Events	Signature	Timestamp
Notary Events	Signature	Timestamp
Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	7/22/2024 10:39:54 AM
Certified Delivered	Security Checked	7/22/2024 10:42:26 AM
Signing Complete	Security Checked	7/22/2024 10:45:03 AM
Completed	Security Checked	7/22/2024 10:45:03 AM
Payment Events	Status	Timestamps